An observational study in Malignant Bowel Obstruction, Cancer Pain and Intestinal Obstruction, sponsored by Fundación Santa Fe de Bogota. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Fundación Santa Fe de Bogota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Malignant bowel obstruction is a frequent complication of advanced cancer, particularly of abdominal and pelvic origin, and most affected patients experience pain. Opioids are the mainstay of analgesic treatment, but some patients have pain that does not respond adequately or cannot tolerate further opioid dose increases. Lidocaine infusions are sometimes used as an adjuvant pain treatment in this setting, but specific evidence is limited to case reports and small series.
This retrospective cohort study will review the medical records of adults with cancer and malignant bowel obstruction who received lidocaine infusions for pain as part of routine palliative care at Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá, Colombia) between 2015 and 2025. The study will describe patient characteristics and lidocaine regimens, and will evaluate changes in pain intensity and opioid requirements before and after the start of the infusion, the proportion of patients with a clinically meaningful pain reduction, adverse events, treatment discontinuation due to toxicity, and hospital outcomes. The investigators will not assign or modify any treatment.
Background: Malignant bowel obstruction (MBO) occurs in 10 to 28% of patients with gastrointestinal cancers and in up to 51% of patients with advanced ovarian cancer. Pain is present in 70 to 90% of patients and is often multifactorial, with visceral, inflammatory and neuropathic components. International supportive care guidelines recommend opioids as the basis of analgesic treatment, together with adjuvants, antisecretory agents and antiemetics. However, a subgroup of patients develops refractory pain or dose-limiting opioid adverse effects. Lidocaine, a voltage-gated sodium channel blocker with additional activity at muscarinic and NMDA receptors, has been used as an adjuvant infusion for refractory cancer pain, but evidence specific to MBO is scarce.
Design: Single-center, observational, retrospective cohort study with descriptive and analytical components, conducted in the context of routine clinical practice. Data sources are the institutional electronic health records.
Population and identification: Adults (18 years or older) with cancer and MBO attended by the palliative care team between 2015 and 2025 who received a lidocaine infusion with analgesic intent. Patients will be identified through institutional databases, palliative care service records and medical orders for lidocaine infusions prescribed by a pain and palliative care specialist or fellow. All consecutive eligible patients will be included (non-probability, convenience sample). Eligibility will be verified in the electronic health record by the research team.
Data collection: Data will be recorded in an institutional REDCap database with a unique pseudonymized code for each participant. Variables include demographic, clinical and oncological characteristics (primary tumor, stage, peritoneal carcinomatosis, active cancer treatment, ECOG performance status), obstruction characteristics (level, grade, diagnostic method), pain type, baseline opioid use and oral morphine milligram equivalents (MME/24 h), concomitant adjuvant treatments (corticosteroids, somatostatin analogues, anticholinergics, ketamine, gabapentinoids), lidocaine regimen (route, initial and maximum dose in mg/kg/h, duration), pain intensity (0 to 10 Numeric Rating Scale, NRS) before and after infusion start, adverse events, reason for infusion discontinuation and hospital discharge destination.
Time windows: Baseline NRS and MME are those recorded within the 24 hours before infusion start; post-infusion values are those recorded at 24 and/or 48 hours after infusion start, using the value closest to each time point.
Outcomes: The primary outcome is the change in pain intensity (NRS) from baseline to 24 to 48 hours after infusion start. Secondary outcomes include the proportion of analgesic responders (reduction of 2 or more NRS points or 30% or more from baseline within 24 to 48 hours), change in MME/24 h, frequency and type of adverse events, discontinuation due to toxicity, lidocaine dosing and duration, and hospital discharge destination.
Statistical analysis: Categorical variables will be summarized as frequencies and proportions and continuous variables as means with standard deviations or medians with interquartile ranges according to their distribution. Paired pre-post comparisons of NRS and MME will use the paired t test or the Wilcoxon signed-rank test as appropriate. The proportion of responders will be reported with 95% confidence intervals. Exploratory subgroup analyses (lidocaine dose, infusion duration, route, baseline pain, ECOG and baseline MME) will use chi-square or Fisher exact tests and t, Mann-Whitney U or Kruskal-Wallis tests as appropriate. Missing data will be described; complete-case analysis will be used if missingness is below 10%, and multiple imputation will be considered otherwise. Given the absence of an external control group and the potential for confounding by indication, all findings will be interpreted as associations without causal inference.
Ethics: The study is classified as minimal risk under Colombian Resolution 8430 of 1993. The protocol (version 1.0, February 18, 2026), including a waiver of informed consent for retrospective record review, was approved by the Comité Corporativo de Ética en Investigación of Fundación Santa Fe de Bogotá (CCEI-19342-2026). Data will be handled in accordance with Colombian Law 1581 of 2012 on personal data protection.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
This study's planned enrollment of 50 is below the median of 151 across 61 observational studies indexed under Cancer Pain.
Browse Cancer Pain studies →Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults (18 years or older) with cancer and malignant bowel obstruction attended by the palliative care team at Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá, Colombia) between 2015 and 2025 who received an intravenous or subcutaneous lidocaine infusion as adjuvant pain treatment in routine clinical practice. Patients will be identified through institutional databases, palliative care service records and medical orders for lidocaine infusions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with cancer and malignant bowel obstruction who received an intravenous or subcutaneous lidocaine infusion as adjuvant analgesia in routine clinical practice between 2015 and 2025. Pain intensity and opioid requirements before and after infusion start will be compared within patients; there is no external control group.
Drug: Lidocaine
Continuous intravenous or subcutaneous lidocaine infusion administered with analgesic intent as adjuvant pain treatment in routine clinical practice, with dose, route and duration determined by the treating team. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.
Change in Pain Intensity on the Numeric Rating Scale (NRS)
Pain intensity measured on the 0 to 10 Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain; higher scores indicate worse pain) as documented in the electronic health record. Baseline is the value recorded closest to infusion start within the 24 hours before; post-infusion values are those recorded closest to 24 and 48 hours after infusion start. The absolute change (post-infusion minus baseline) will be reported.
Time frame: Baseline (within 24 hours before infusion start), 24 hours and 48 hours after infusion start
Percentage of Patients With a Clinically Meaningful Analgesic Response
Analgesic response is defined as a reduction of 2 or more points on the 0 to 10 Numeric Rating Scale (NRS) or a reduction of 30% or more from the baseline NRS within the first 24 to 48 hours after infusion start. The percentage of responders will be reported with its 95% confidence interval.
Time frame: 24 to 48 hours after infusion start
Change in Opioid Requirements in Oral Morphine Milligram Equivalents per 24 Hours (MME/24 h)
Total daily opioid dose converted to oral morphine milligram equivalents (MME/24 h). Baseline is the value within the 24 hours before infusion start; post-infusion values are those closest to 24 and 48 hours after infusion start. The absolute change (post-infusion minus baseline) will be reported.
Time frame: Baseline (within 24 hours before infusion start), 24 hours and 48 hours after infusion start
Number of Patients With Adverse Events Attributed to Lidocaine
Frequency, type (dizziness, nausea, somnolence, paresthesia, hypotension, arrhythmia, seizure, central nervous system toxicity, other) and clinical severity of adverse events documented in the medical record as attributable to the lidocaine infusion.
Time frame: From infusion start until the end of the infusion
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be shared. Data are obtained from a retrospective review of medical records under a waiver of informed consent and are protected under Colombian personal data protection law (Law 1581 of 2012). Aggregated results will be published in a peer-reviewed journal.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Santa Fe de Bogota